Valneva Se ADR (VALN)

$9.33 -0.23 (-2.41%)
Market Cap 823.18M
Revenue (ttm) 183.50M
Net Income (ttm) -13.25M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7.22%
Debt to Equity Ratio 1.11
Volume 12,600
Avg Vol 19,502
Day's Range N/A - N/A
Shares Out 86.11M
Stochastic %K 38%
Beta 1.84
Analysts Strong Sell
Price Target $12.89

Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-a...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 2 28 07 37 10
Fax: 33 2 28 07 37 11
Website: valneva.com
Address:
6 rue Alain Bombard, Saint-Herblain, France
Night_Owl_Biotech
Night_Owl_Biotech Feb. 6 at 2:23 AM
Of the 63 commercial-stage non-oncology focused bios with market caps ranging from $750MM to $15B, only 8 are trading higher after the worst 2 days for the XBI since April 2025. $OCUL was up we suspect due to renewed hope for a Sanofi buyout. Recall Sanofi offered $16 per share to acquire OCUL last September. OCUL closed today (6 months later) at $8.91. $SUPN has been quiet (no PR since November) but perhaps SUPN's gains reflect the virtue of diversity. $TWST released Q126 financials Monday after the close. TWST is 1 of the 8 higher the last 2 days. $VALN focuses on vaccines which has been a lousy space (of course excluding DVAX). $ORG had finally been running after trading between $6 & $8 a share since Halloween. One has to wonder if OGN under $8 is a memory. OGN generates $6B/year in sales but has a leveraged capital structure. If OGN ever traded at peer multiples...
0 · Reply
1Darknight
1Darknight Feb. 5 at 11:31 PM
$VALN focus on innovative vaccines,, including Lyme disease (partnered with Pfizer) and chikungunya, targets high unmet medical needs worldwide….
0 · Reply
1Darknight
1Darknight Feb. 5 at 11:27 PM
$VALN
0 · Reply
MacroMaster
MacroMaster Feb. 4 at 3:29 PM
$VALN is a vaccine company (Valneva); it has a commercial cholera vaccine and is developing others, but faces competition and the high cost of vaccine development.
0 · Reply
ajmore
ajmore Feb. 4 at 8:58 AM
$PFE $VALN lyme vaccine phase 3 data any moment!
2 · Reply
ajmore
ajmore Feb. 3 at 6:48 AM
$VALN Valneva start and instituto Butantan start pilot chikungunya vaccination campaign in Brazil.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 21 at 2:10 AM
$VALN RSI: 62.79, MACD: 0.3451 Vol: 0.74, MA20: 9.24, MA50: 8.98 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
NVDAMillionaire
NVDAMillionaire Jan. 20 at 7:54 PM
$VALN Really good write-up that perfectly summarizes VALN's present situation. So if you want to bring your VALN knowledge up to date or just discover VALN, this is required reading. https://everyticker.com/quote/VALN/analysis/valneva-s-lyme-vaccine-moment-can-a-blockbuster-pipeline-offset-chikungunya-s-us-implosion-nasdaq-valn
0 · Reply
notreload_ai
notreload_ai Jan. 20 at 11:20 AM
$VALN voluntarily withdraws its IXCHIQ chikungunya vaccine from the U.S. following FDA suspension and a serious adverse event report, while maintaining licenses in Europe, Canada, UK, and Brazil. https://notreload.xyz/valneva-pulls-chikungunya-vaccine-ixchiq-from-us-market/
1 · Reply
Siuolman58
Siuolman58 Jan. 20 at 11:05 AM
$VALN Today is the day to buy all u can.
0 · Reply
Latest News on VALN
Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®

Feb 3, 2026, 1:00 AM EST - 3 days ago

Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®

Valneva withdraws application for standard US approval of its chikungunya shot

Jan 19, 2026, 2:00 PM EST - 17 days ago

Valneva withdraws application for standard US approval of its chikungunya shot

Valneva Provides Update on Chikungunya Vaccine IXCHIQ®

Jan 19, 2026, 12:00 PM EST - 17 days ago

Valneva Provides Update on Chikungunya Vaccine IXCHIQ®

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

Jan 9, 2026, 1:00 AM EST - 4 weeks ago

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

Valneva SE - Declaration of voting rights - December 2025

Jan 8, 2026, 12:30 PM EST - 4 weeks ago

Valneva SE - Declaration of voting rights - December 2025

Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement

Dec 31, 2025, 11:45 AM EST - 5 weeks ago

Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®

Dec 10, 2025, 11:45 AM EST - 2 months ago

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®

VALNEVA Declaration of shares and voting rights: November 30, 2025

Dec 5, 2025, 12:34 PM EST - 2 months ago

VALNEVA Declaration of shares and voting rights: November 30, 2025

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

Nov 26, 2025, 12:30 PM EST - 2 months ago

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

PFE

Valneva to Further Consolidate its Operations in France

Nov 26, 2025, 11:30 AM EST - 2 months ago

Valneva to Further Consolidate its Operations in France

Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study

Nov 26, 2025, 6:37 AM EST - 2 months ago

Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate

Nov 26, 2025, 1:00 AM EST - 2 months ago

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate

Valneva SE (VALN) Q3 2025 Earnings Call Transcript

Nov 20, 2025, 3:23 PM EST - 2 months ago

Valneva SE (VALN) Q3 2025 Earnings Call Transcript

Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates

Nov 20, 2025, 1:00 AM EST - 2 months ago

Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Nov 4, 2025, 1:00 AM EST - 3 months ago

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Oct 27, 2025, 12:45 PM EDT - 3 months ago

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates

Oct 6, 2025, 11:35 AM EDT - 4 months ago

Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®

Sep 30, 2025, 1:00 AM EDT - 4 months ago

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

Sep 3, 2025, 1:00 AM EDT - 5 months ago

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday

Aug 25, 2025, 12:02 PM EDT - 5 months ago

Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday

KDP VENU

Johnson Fistel Investigates Valneva Following FDA Suspension

Aug 25, 2025, 10:43 AM EDT - 5 months ago

Johnson Fistel Investigates Valneva Following FDA Suspension

Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US

Aug 25, 2025, 10:29 AM EDT - 5 months ago

Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US

FDA suspends Valneva's chikungunya vaccine license in the U.S.

Aug 25, 2025, 1:16 AM EDT - 5 months ago

FDA suspends Valneva's chikungunya vaccine license in the U.S.

Valneva Announces FDA's Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.

Aug 25, 2025, 1:00 AM EDT - 5 months ago

Valneva Announces FDA's Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Aug 18, 2025, 1:00 AM EDT - 6 months ago

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Valneva SE (VALN) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 3:20 PM EDT - 6 months ago

Valneva SE (VALN) Q2 2025 Earnings Call Transcript

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

Aug 12, 2025, 1:00 AM EDT - 6 months ago

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

Aug 7, 2025, 1:18 AM EDT - 6 months ago

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate

Jul 29, 2025, 10:00 AM EDT - 6 months ago

AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate

Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly

Jul 11, 2025, 11:35 AM EDT - 7 months ago

Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly

Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults

Jul 11, 2025, 8:18 AM EDT - 7 months ago

Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

Jun 26, 2025, 1:00 AM EDT - 8 months ago

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance

Jun 25, 2025, 11:45 AM EDT - 8 months ago

Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance

UK's MHRA suspends Valneva's chikungunya vaccine for elderly

Jun 9, 2025, 10:29 AM EDT - 8 months ago

UK's MHRA suspends Valneva's chikungunya vaccine for elderly

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

Jun 5, 2025, 11:45 AM EDT - 8 months ago

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Jun 4, 2025, 1:00 AM EDT - 8 months ago

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Valneva to Participate at U.S. and European Investor Conferences in June

May 26, 2025, 11:30 AM EDT - 9 months ago

Valneva to Participate at U.S. and European Investor Conferences in June

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

May 12, 2025, 1:00 AM EDT - 9 months ago

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

Valneva SE (VALN) Q1 2025 Earnings Call Transcript

May 9, 2025, 9:47 AM EDT - 9 months ago

Valneva SE (VALN) Q1 2025 Earnings Call Transcript

Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance

May 8, 2025, 12:30 AM EDT - 9 months ago

Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

May 7, 2025, 11:45 AM EDT - 9 months ago

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people

May 7, 2025, 8:40 AM EDT - 9 months ago

Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 7, 2025, 1:00 AM EDT - 9 months ago

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

Apr 26, 2025, 1:10 PM EDT - 10 months ago

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Apr 18, 2025, 4:00 AM EDT - 10 months ago

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Apr 16, 2025, 11:45 AM EDT - 10 months ago

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine

Apr 14, 2025, 2:28 PM EDT - 10 months ago

Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine

Night_Owl_Biotech
Night_Owl_Biotech Feb. 6 at 2:23 AM
Of the 63 commercial-stage non-oncology focused bios with market caps ranging from $750MM to $15B, only 8 are trading higher after the worst 2 days for the XBI since April 2025. $OCUL was up we suspect due to renewed hope for a Sanofi buyout. Recall Sanofi offered $16 per share to acquire OCUL last September. OCUL closed today (6 months later) at $8.91. $SUPN has been quiet (no PR since November) but perhaps SUPN's gains reflect the virtue of diversity. $TWST released Q126 financials Monday after the close. TWST is 1 of the 8 higher the last 2 days. $VALN focuses on vaccines which has been a lousy space (of course excluding DVAX). $ORG had finally been running after trading between $6 & $8 a share since Halloween. One has to wonder if OGN under $8 is a memory. OGN generates $6B/year in sales but has a leveraged capital structure. If OGN ever traded at peer multiples...
0 · Reply
1Darknight
1Darknight Feb. 5 at 11:31 PM
$VALN focus on innovative vaccines,, including Lyme disease (partnered with Pfizer) and chikungunya, targets high unmet medical needs worldwide….
0 · Reply
1Darknight
1Darknight Feb. 5 at 11:27 PM
$VALN
0 · Reply
MacroMaster
MacroMaster Feb. 4 at 3:29 PM
$VALN is a vaccine company (Valneva); it has a commercial cholera vaccine and is developing others, but faces competition and the high cost of vaccine development.
0 · Reply
ajmore
ajmore Feb. 4 at 8:58 AM
$PFE $VALN lyme vaccine phase 3 data any moment!
2 · Reply
ajmore
ajmore Feb. 3 at 6:48 AM
$VALN Valneva start and instituto Butantan start pilot chikungunya vaccination campaign in Brazil.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 21 at 2:10 AM
$VALN RSI: 62.79, MACD: 0.3451 Vol: 0.74, MA20: 9.24, MA50: 8.98 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
NVDAMillionaire
NVDAMillionaire Jan. 20 at 7:54 PM
$VALN Really good write-up that perfectly summarizes VALN's present situation. So if you want to bring your VALN knowledge up to date or just discover VALN, this is required reading. https://everyticker.com/quote/VALN/analysis/valneva-s-lyme-vaccine-moment-can-a-blockbuster-pipeline-offset-chikungunya-s-us-implosion-nasdaq-valn
0 · Reply
notreload_ai
notreload_ai Jan. 20 at 11:20 AM
$VALN voluntarily withdraws its IXCHIQ chikungunya vaccine from the U.S. following FDA suspension and a serious adverse event report, while maintaining licenses in Europe, Canada, UK, and Brazil. https://notreload.xyz/valneva-pulls-chikungunya-vaccine-ixchiq-from-us-market/
1 · Reply
Siuolman58
Siuolman58 Jan. 20 at 11:05 AM
$VALN Today is the day to buy all u can.
0 · Reply
Siuolman58
Siuolman58 Jan. 18 at 1:05 PM
Infectious disease expert reveals the viruses to worry about in 2026 $VALN https://www.dailymail.co.uk/health/article-15446085/infectious-disease-expert-viruses-pandemic-warning.html?ito=native_share_article-nativemenubutton
0 · Reply
Siuolman58
Siuolman58 Jan. 15 at 6:30 PM
$VALN back down to pick up some more
0 · Reply
discountcroesus1
discountcroesus1 Jan. 11 at 3:11 PM
$VALN It smells more and more like a deal with Pfizer... Our friend @Creisi has been saying it for a while now, and it's gone unnoticed. This guy is very well-informed... he proved it with MLTX, which has almost doubled in the last two days, and it's probably not over because, according to him, Merck will buy MLTX within a few weeks. But maybe even more interestingly, it's Biomea that has caught his attention, with a potential 15x increase by autumn 2026, and maybe even 50x by autumn 2027.
0 · Reply
Siuolman58
Siuolman58 Jan. 10 at 11:34 PM
$VALN I smell a deal!!!
0 · Reply
buzzkiller
buzzkiller Jan. 9 at 4:13 PM
$VALN buy out incoming. Hastily announced JPM San Francisco meetings for today. Could be as soon as today.
0 · Reply
Creisi
Creisi Jan. 8 at 4:52 PM
$BMEA $MLTX $VALN Love Biomea Fusion. Icovamenib is a definite blockbuster even better than you think. Amazing drug. $BMEA has now tied $MLTX for the best clinical biopharma investment to make in 2026 and they'll both get a combined total of about 75% of my investment fund. $BMEA will be number 1 as soon as Merck confirms their buy out of $MLTX . My candidate for most likely surprise buyout is VALN. There's simply no way Pfizer is paying VALN a 22% royalty on all Lyme Disease Vaccine sales. Plus, $PFE already own 10% $VALN So $VALN will get at least 15%. I hold a few others that were already purchased, so they're excluded. I'm exploring other candidates to add and will have new choices by January 30, the date I expect MLTX will be part of Merck.
2 · Reply
Creisi
Creisi Jan. 7 at 7:51 PM
$VALN Confirmed. Pfizer's Business Development Department have Valneva on its short list of potential BuyOut candidates. I have no news of any confirmed offer, but this one is perhaps the most obvious in all of Pharma. Pfizer own almost 10% of the company and would need to pony up 22% Royalty Checks annually on all Lyme Vaccine sales. No Big Pharma company pays that kind of royalty check to a small biopharma company they could simply buy and move to the Asset column of their balance sheet. Pfizer will buy these guys before the fall of 2026. Super obvious!
0 · Reply
Creisi
Creisi Jan. 6 at 7:43 PM
$ABVX $VALN I think Pfizer, who already own 9% of VALN will Buy the Out this year instead of giving them a 22% Royalty check annually for the Lyme Disease Vaccine which is nearing BLA submission by the 4th quarter of 2026. I don't have any feelers out on this but damn it makes enough sense that I think I will look into it.
0 · Reply
DaxCo
DaxCo Jan. 6 at 4:03 PM
$ABVX $VALN same same but different. What do you think?
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 2 at 4:41 AM
$VALN Current Stock Price: $8.86
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 31 at 5:41 PM
$VALN
0 · Reply
Siuolman58
Siuolman58 Dec. 30 at 8:56 PM
$VALN Ran the stops!! Collected some nice ones!
0 · Reply